In a phase 2b trial targeting EGFR lung cancer, the molecule met the primary endpoint ... PFS was 9.7 months versus 12 months ...

GAGome score had 90 percent sensitivity, 51 percent specificity for radiological recurrence, with AUC of 0.73 for nonmetastatic clear-cell renal cell carcinoma.

ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid ...